Related Experiment Video
Updated: Jan 11, 2026
12:09
Studying Food Reward and Motivation in Humans
Published on: March 19, 2014
24.1K
GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Use Disorders
Jingchuan Guo1, Matthew R Hayes2, Lorenzo Leggio3
1Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida 32610.
Summary
Glucagon-like peptide-1 receptor (GLP-1R) agonists show promise beyond diabetes and obesity. These drugs target brain receptors, offering potential treatments for addictive behaviors like binge eating and substance use disorders.
Area of Science:
- Neuroscience
- Endocrinology
- Pharmacology
Background:
- Glucagon-like peptide-1 receptor (GLP-1R) agonists are established treatments for type 2 diabetes and obesity.
- Emerging research suggests GLP-1R agonists have broader therapeutic applications.
- These agonists act on receptors in both peripheral tissues and the central nervous system.
Purpose of the Study:
- To review the expanding therapeutic potential of GLP-1R agonists.
- To explore the role of GLP-1R agonists in treating pathological consummatory behaviors.
- To consolidate findings from basic science, clinical data, and real-world observations.
Main Methods:
- Review of preclinical studies using animal models.
- Analysis of human clinical trial data.
- Synthesis of real-world observational evidence.
Main Results:
- GLP-1R agonists effectively cross the blood-brain barrier to engage central receptors.
- Evidence supports the efficacy of GLP-1R agonists in managing binge-eating disorders.
- GLP-1R agonists demonstrate potential in treating alcohol and other substance use disorders.
Conclusions:
- GLP-1R agonists represent a promising therapeutic class for a range of behavioral disorders.
- Targeting the GLP-1R in the brain offers a novel strategy for addiction treatment.
- Further research and clinical application of GLP-1R agonists in behavioral health are warranted.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
01:30Regulation of Food Intake
2.3K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
2.3K
01:15G Protein-coupled Receptors
16.4K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.4K
01:06Oral Hypoglycemic Agents: Glinides
577
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
577
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
511
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
511
01:25Drug-Receptor Interaction: Agonist
3.8K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.8K